Inotek Pharmaceuticals to Present at the BIO CEO and Investor Conference
10 Febbraio 2017 - 3:00PM
Business Wire
Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a
clinical-stage biopharmaceutical company focused on the discovery,
development and commercialization of therapies for ocular diseases,
today announced that David P. Southwell, President and Chief
Executive Officer of Inotek, will present at the BIO CEO and
Investor Conference on Tuesday, February 14, 2017 at 1:00pm EST at
the Waldorf Astoria Hotel in New York City.
About Inotek Pharmaceuticals CorporationInotek
Pharmaceuticals is a clinical-stage biopharmaceutical company
focused on the discovery, development and commercialization of
therapies for glaucoma and other eye diseases. The Company’s lead
product candidate, trabodenoson, is a first-in-class selective
adenosine mimetic currently in Phase 3 development. Trabodenoson
was developed in Inotek’s laboratories and is designed to restore
the eye’s natural pressure control mechanism. Additionally, the
Company is evaluating the potential for selective adenosine
mimetics to address optic neuropathies and other degenerative
retinal diseases. For more information, please visit
www.inotekpharma.com. The inclusion of our website address here and
elsewhere in this press release does not include or incorporate by
reference the information on our website into this press
release.
Forward-Looking StatementsThis press release contains
forward-looking statements, which are subject to substantial risks,
uncertainties and assumptions. You should not place reliance on
these statements often include words such as "believe," "expect,"
"anticipate," "intend," "plan," "estimate," "seek," "will," "may"
or similar expressions. Although the Company believes that the
expectations reflected in the forward-looking statements are
reasonable, the Company cannot guarantee such outcomes.
Accordingly, you should not place undue reliance on these
forward-looking statements. All such statements speak only as of
the date made, and the Company undertakes no obligation to update
or revise publicly any forward-looking statements, whether as a
result of new information, future events or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170210005330/en/
Inotek Contact:Claudine Prowse, PhD, 781-552-4305Vice
President, Strategy and IROIR@inotekpharma.com
Grafico Azioni INOTEK PHARMACEUTICALS CORP (NASDAQ:ITEK)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni INOTEK PHARMACEUTICALS CORP (NASDAQ:ITEK)
Storico
Da Giu 2023 a Giu 2024
Notizie in Tempo Reale relative a Inotek Pharmaceuticals Corp. (delisted) (NASDAQ): 0 articoli recenti
Più Inotek Pharmaceuticals Corp. (MM) Articoli Notizie